Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myelin basic protein (MBP)-reactive T cells are a subset of autoreactive T lymphocytes that specifically recognize epitopes derived from myelin basic protein, a key structural component of the myelin sheath in the central nervous system. These cells play a significant role in the pathogenesis of autoimmune demyelinating diseases, most notably multiple sclerosis (MS). These autoreactive T cells are activated, clonally expanded, and accumulate within the brain compartment. Both CD4+ helper and CD8+ cytotoxic MBP-reactive T cell subsets have been identified. Activation can occur through direct recognition of self-MBP peptides presented by MHC molecules on antigen-presenting cells, or through molecular mimicry from microbial peptides.
T cell vaccination aims to induce regulatory networks that suppress or deplete circulating autoreactive populations. Other drugs (immunosuppressants, anti-inflammatories) have broader effects on the immune system.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myelin Basic Protein-Reactive T Cell (MBP-reactive T cell).